Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: J&J’s Spravato on track for blockbuster status; US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and Legend buyout rumors validate China biotech.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 19 July 2024, including: Johnson & Johnson’s Spravato on track for blockbuster status; US uptake of Rezzdifra held up by payers; CNS drugs are surprisingly valuable; obesity rules large cap stocks; and Legend Biotech Corp. buyout rumors validate China biotech.
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J&J’s Spravato On Track To Be A Blockbuster, Five Years In" - Scrip, 17 Jul, 2024.)
(Also see "Rezdiffra Uptake Held Up By Payers, But Not Biopsy Requirements" - Scrip, 15 Jul, 2024.)
(Also see "CNS Drugs Are Surprisingly Valuable" - Scrip, 15 Jul, 2024.)
(Also see "Obesity Rules Large-Cap Stocks In First Half Of 2024" - Scrip, 16 Jul, 2024.)
(Also see "Legend Buyout Report Boosts, Validates China Biotech" - Scrip, 16 Jul, 2024.)